XML 59 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets - Nucynta Commercialization Agreement - Table (Details) - USD ($)
$ in Thousands
1 Months Ended 2 Months Ended 3 Months Ended 8 Months Ended 9 Months Ended 10 Months Ended 12 Months Ended 26 Months Ended
Feb. 05, 2020
Dec. 31, 2018
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Nov. 07, 2018
Dec. 31, 2019
Feb. 29, 2020
Feb. 06, 2020
Nov. 08, 2018
Jan. 31, 2018
Amortization expense     $ (16,795) $ (3,688)   $ (43,885) $ (11,064)     $ (126,340)      
Intangible assets, net     352,699   $ 352,699 352,699              
Nucynta Products                          
Gross carrying amount     521,170   521,170 521,170     $ 154,089        
Accumulated amortization     (168,471)   (168,471) (168,471)     (124,586)        
Intangible assets, net     352,699   352,699 352,699     29,503        
Nucynta Commercialization Agreement | Nucynta Products                          
Gross carrying amount   $ 154,089 521,170   521,170 521,170     154,089       $ 515,627
Amortization expense $ (1,754) (2,172)     (42,131)     $ (107,662) (14,752)        
Accumulated amortization   (109,834) (168,471)   (168,471) (168,471)     (124,586)        
Adjustment due to remeasurement of liability                       $ (369,581)  
Additional costs incurred                     $ 367,081 $ 8,043  
Intangible assets, net   $ 44,255 $ 352,699   $ 352,699 $ 352,699     $ 29,503       $ 515,627